HK Stock Market Move | Jiangsu Hengrui Pharmaceuticals (01276) rose more than 7% in the morning, reaching a new high in stock prices. Rituximab can beused for a new indication and submitted for listing.

Jiangsu Hengrui Pharmaceuticals (01276) rose more than 7% in the morning, reaching a high of HK$91, setting a new record high for the company. As of the time of reporting, the stock was up 7.18% at HK$91, with a turnover of HK$2.98 billion. On the news front, a subsidiary of Jiangsu Hengrui Pharmaceuticals received a "Notice of Acceptance" from the National Medical Products Administration for the drug injection rituximab (SHR-A1811), which is used to treat locally advanced or metastatic HER2-positive breast cancer in adults who have previously received one or more HER2-targeted therapies. Tianfeng pointed out that Jiangsu Hengrui Pharmaceuticals achieved a net profit attributable to shareholders of 4.45 billion yuan in the first half of the year, an increase of 29.67% year-on-year; net profit attributable to shareholders in the second quarter of 2025 was 2.576 billion yuan, an increase of 24.88% year-on-year. The company's innovative drugs entered a phase of rapid growth in the first half of 2025, with profits from internationalization continuing to increase. Overseas licensing revenue continued to grow, reaching a total of $700 million in upfront payments so far in 2025. With a continuously enriched pipeline, the company is expected to maintain high-speed growth in innovative drugs over the next three years. The company is continuously producing products with significant potential. In the first half of 2025, the company had 15 innovative molecules developed in-house entering clinical trials for the first time. Considering the continuous growth in production of innovative drug products, the company retains a "buy" rating.